How much does a box of Dacomitinib cost?

Dacomitinib is a second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC). It was developed by Pfizer and approved by the U.S. Food and Drug Administration (FDA) in 2018.

Dacomitinib is mainly targeted at metastatic NSCLC patients with EGFR mutations. Common EGFR mutation types include L858R mutation and Exon 19Deletion mutations. Unlike first-generation EGFR-TKIs (such as gefitinib and erlotinib), dacomitinib (dacomitinib) is an irreversible tyrosine kinase inhibitor that inhibits EGFR activity more persistently. Its mechanism of action is to irreversibly bind to the ATP binding site of EGFR, blocking EGFR-mediated signal transduction and inhibiting the proliferation and survival of tumor cells.

Dacomitinib (Dacomitinib) is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically. The price of 15mg*30 tablets is about more than one thousand yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The price of the European version of Pfizer's original drug abroad is about more than 20,000 yuan, which is very expensive. The cheaper ones abroad are Laotian generic drugs. The specifications are 45mg*30 and the price is about the same as before. It is three times cheaper than domestic drugs, and the ingredients are basically the same as the original drugs.

The ARCHER 1050clinical trial showed thatdacomitinib was superior to gefitinib in extending progression-free survival (PFS) and overall survival (OS). Trial results show that usingdacomitinib (dacomitinib)The median progression-free survival of patients in the gefitinib group was 14.7 months, compared with 9.2 months in the gefitinib group. In addition, overall survival also improved for patients in the dacomitinib group. However, Dacomitinib has better adverse reactions than . Common side effects include rash, diarrhea, stomatitis and nail disease. Nonetheless, these side effects are often manageable, and patients can still benefit from them through dose adjustment and symptomatic treatment.

In clinical practice, doctors will choose the most appropriate treatment plan based on the patient's specific situation, includingEGFR mutation type, drug resistance and overall health status. Although Dacomitinib provides an effective treatment option for EGFRmutated NSCLC patients, with the emergence of third-generation EGFR-TKIs (such as osimertinib), treatment strategies are constantly being updated and optimized.